ESWT for Shoulder Pain in Patients With Brain Damage

Sponsor
Bundang CHA Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04320108
Collaborator
(none)
40
1
2
8.3
4.8

Study Details

Study Description

Brief Summary

This study aimed to investigate the efficacy and safety of extracorporeal shockwave therapy (ESWT) for upper extremity pain related to spasticity in patients with spinal cord injury.

Condition or Disease Intervention/Treatment Phase
  • Device: Extracorporeal shockwave therapy
N/A

Detailed Description

6 times of ESWT (3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range) on subscapularis and lesser and greater tuberlces of humerus to reduce pain in patients with brain damage

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effects of Extracorporeal Shockwave Therapy (ESWT) for Shoulder Pain in Patients With Brain Damage
Actual Study Start Date :
May 29, 2020
Anticipated Primary Completion Date :
Oct 31, 2020
Anticipated Study Completion Date :
Feb 5, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental group

3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range

Device: Extracorporeal shockwave therapy
Extracorporeal shockwave therapy 6 times during 2 weeks

Sham Comparator: Control group

Sham therapy

Device: Extracorporeal shockwave therapy
Extracorporeal shockwave therapy 6 times during 2 weeks

Outcome Measures

Primary Outcome Measures

  1. Numerical rating scale (NRS) [Up to 4 weeks (baseline, after each treatment during 2 weeks, 2 weeks + 1 day, 4 weeks)]

    Pain intensity (0-10, ordinal scale)

Secondary Outcome Measures

  1. Shoulder Pain and Disability Index (SPADI) [Up to 4 weeks (baseline, 2 weeks + 1 day, 4 weeks)]

    Scoring scale consist of 5 pain scale and 8 disability scale, in %, 0 (best) to 100 (worst)

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Brain damaged patient confirmed in the brain image

  • 1 month after brain damage

  • Pain in hemiplegic shoulder areas more than 4 points on the numerical scale (NRS)

  • Cognitive functions that can clearly point out NRS with more than 15 points in the mini mental state examination (MMSE)

  • Age: 20 and older

  • Person who has agreed in writing to decide his or her participation and comply with the precautions

Exclusion Criteria:
  • Pain due to trauma

  • Injection treatments two weeks before participating in the study

  • Severe coagulopathy (excluding antiplatelet use)

  • Impaired cognition

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Rehabilitation Medicine, CHA Bundang Medical Center Seongnam Korea, Republic of 13496

Sponsors and Collaborators

  • Bundang CHA Hospital

Investigators

  • Principal Investigator: MinYoung Kim, MD, PhD, Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
MinYoung Kim, MD, PhD, Principal professor of Rehabilitation Medicine, Bundang CHA Hospital
ClinicalTrials.gov Identifier:
NCT04320108
Other Study ID Numbers:
  • ESWTbraindamage
First Posted:
Mar 24, 2020
Last Update Posted:
Nov 4, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by MinYoung Kim, MD, PhD, Principal professor of Rehabilitation Medicine, Bundang CHA Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 4, 2020